受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | Idronoxil, Dehydroequol, NV 06, PXD | Storage (From the date of receipt) |
3 years -20°C powder | |
化学式 | C15H12O3 |
|||
分子量 | 240.25 | CAS No. | 81267-65-4 | |
Solubility (25°C)* | 体外 | DMSO | 48 mg/mL (199.79 mM) | |
Ethanol | 48 mg/mL (199.79 mM) | |||
Water | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | Phenoxodiol (Haginin E, Idronoxil, Dehydroequol, NV 06, PXD) is an isoflavone analog with antineoplastic activity that activates the caspase system, inhibits XIAP (X-linked inhibitor of apoptosis), and disrupts FLICE inhibitory protein (FLIP) expression, resulting in tumor cell apoptosis. Phenoxodiol also inhibits DNA topoisomerase II. |
---|---|
in vitro | Primary ovarian cancer cells, isolated from ascitic fluids of ovarian cancer patients, resistant to conventional chemotherapy, undergo apoptosis following phenoxodiol treatment. This effect is dependent upon the activation of the caspase system, inhibiting XIAP, an inhibitor of apoptosis, and disrupting FLICE inhibitory protein (FLIP) expression through the Akt signal transduction pathway. Phenoxodiol is an efficient inducer of cell death in ovarian cancer cells and sensitizes the cancer cells to Fas-mediated apoptosis.[1] |
in vivo | In an in vivo colon cancer model, Balb/C mice administered low-dose Phenoxodiol (PXD), exhibits significantly reduced tumour growth rates and prolonged survival (in 40% of the animals).[4] |
細胞アッセイ | 細胞株 | primary ovarian cancer cells |
---|---|---|
濃度 | 0.1 μg/ml, 1 μg/ml, 10 μg/ml | |
反応時間 | 24 h | |
実験の流れ | Cells are treated in the presence or absence of 500 ng/ml Fas-antibody in Optimem for 24 h or with 0.1, 1 or 10 μg/ml phenoxodiol, NV03, NV05 or NV07 in Optimem for 24 h. For treatment with phenoxodiol and caspase inhibitors, 10 μg/ml phenoxodiol is used alone, or in combination with 20 μM general caspase-inhibitor Z-VADFMK and incubated for 24 h. |
|
動物実験 | 動物モデル | 7–8-week-old female Balb/C mice |
投薬量 | 10 mg/kg, 20 mg/kg | |
投与方法 | IP |
Evaluation of therapeutic potential of phenoxodiol, a novel isoflavone analog, in renal cancer cells [ Anticancer Res, 2018, 38(10):5709-5716] | PubMed: 30275191 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。